Tranexamic Acid (TXA)

Tranexamic Acid

The CRASH-2 2 (Clinical Randomisation of an Anti-fibrinolytic in Significant Haemorrhage 2) study involved the randomisation of over 20,000 patients with, or at risk of significant haemorrhage in 40 countries. The study demonstrated a 32% reduction in death due to haemorrhage, when tranexamic acid is administered within 1 h of injury. The study concluded that tranexamic acid safely reduced the risk of death in bleeding trauma patients, and should be considered for use in practice.

Following the publication of the study, the Trust has been working with Professor Stuart Logan, Director of the Peninsula National Institute of Health Research's Collaboration for Leadership in Applied Health Research and Care to implement the intervention across the South West.

For further information please contact Adrian South, Deputy Director of Clinical Care at adrian.south@swast.nhs.uk

Local Resources

Published Evidence

TXA image

Email this page Print page

News

CUTTING EDGE TRAINING TECHNOLOGY ON DISPLAY AT LOCATIONS ACROSS DEVON
CUTTING edge technology that is helping to train the paramedics of the future is going to be on display at locations across Devon and you are invited to come along for a demonstration.
22/03/2017

Rounded corners
Rounded corners
 
© South Western Ambulance Service NHS Foundation Trust 2017 Design by Precedent | Powered by Sitekit